Compare ZGM & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZGM | PASG |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | Macau | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 28.3M |
| IPO Year | 2025 | 2020 |
| Metric | ZGM | PASG |
|---|---|---|
| Price | $2.12 | $9.33 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | 16.6K | ★ 57.7K |
| Earning Date | 01-06-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.81 | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $3,163,046.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.44 | ★ N/A |
| Revenue Growth | ★ 55.90 | N/A |
| 52 Week Low | $1.90 | $5.12 |
| 52 Week High | $4.51 | $20.00 |
| Indicator | ZGM | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 42.31 | 36.51 |
| Support Level | $2.00 | $8.86 |
| Resistance Level | $2.30 | $10.63 |
| Average True Range (ATR) | 0.26 | 1.38 |
| MACD | -0.04 | -0.45 |
| Stochastic Oscillator | 15.00 | 3.76 |
Zenta Group Co Ltd is a professional services provider in Macau, offering industrial park consulting services, business investment consulting services through LIC, and the sale of fintech products and services through LFT. Its industrial park consulting services focus on the pre-development stage, assisting with applications and negotiations for industrial park projects with PRC government authorities, with plans to expand into post-development services through LMS. The business investment consulting services mainly involve assisting clients in acquiring equity stakes in technology firms, private equity management firms, and industrial park project firms, supported by third-party professionals. The Group operates in Macau and the PRC, generating the majority of its revenue from the PRC.
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.